Methods and compositions for treating cancer using peptide nucleic acid-based agents
US-10113169-B2 · Oct 30, 2018 · US
US10385100B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10385100-B2 |
| Application number | US-201615221021-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 27, 2016 |
| Priority date | Oct 29, 2012 |
| Publication date | Aug 20, 2019 |
| Grant date | Aug 20, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Peptide nucleic acids containing thymidine and 2-aminopyridine (M) nucleobases formed stable and sequence selective triple helices with double stranded RNA at physiologically relevant conditions. The M-modified PNA displayed unique RNA selectivity by having two orders of magnitude higher affinity for the double stranded RNAs than for the same DNA sequences. Preliminary results suggested that nucleobase-modified PNA could bind and recognize double helical precursors of microRNAs.
Opening claim text (preview).
What is claimed is: 1. A peptide nucleic acid, comprising: a polypeptide comprising a series of N-(2-aminoethyl)-glycines, each N-(2-aminoethyl)-glycine being ligated to a respective Base, and wherein at least one of the respective Bases is 2-aminopyridine: such that at least one N-(2-aminoethyl)-glycine ligated to a Base is 2-aminopyridine-ligated to a N-(2-aminoethyl)-glycine: further comprising at least one basic amino acid ligated to the polypeptide. 2. The peptide nucleic acid according to claim 1 , wherein the at least one basic amino acid comprises at least one terminal lysine ligated to the polypeptide. 3. The peptide nucleic acid according to claim 1 , wherein at least four bases are 2-aminopyridine. 4. The peptide nucleic acid according to claim 1 , wherein at least two sequential bases are 2-aminopyridine. 5. The peptide nucleic acid according to claim 1 , wherein the polypeptide comprises at least six sequential base-ligated N-(2-aminoethyl)-glycines. 6. The peptide nucleic acid according to claim 1 , in combination with a double stranded RNA, wherein the peptide nucleic acid forms a base sequence selective triple helix with the double stranded RNA substantially without strand invasion. 7. The peptide nucleic acid according to claim 1 , wherein the peptide nucleic acid is configured to form a triple helix with a double stranded RNA having a corresponding base sequence with the peptide nucleic acid, substantially without strand invasion, which is stable at pH 7.4. 8. The peptide nucleic acid according to claim 7 , wherein the peptide nucleic acid is configured to form the triple helix with the double stranded RNA, in a base sequence-selective manner at pH 7.4 at a temperature of 37° C. in an aqueous buffer comprising 2 mM MgCl 2 , 90-mM KCl, 10 mM NaCl, and 50 mM potassium phosphate. 9. A peptide nucleic acid (PNA), comprising: a polypeptide comprising a series of at least six N-(2-aminoethyl)-glycines, each N-(2-aminoethyl)-glycine being ligated to a respective Base, wherein at least one respective Base comprises 2-aminopyridine, further comprising at least one basic amino acid ligated to the polypeptide. 10. The peptide nucleic acid according to claim 9 , wherein the at least one basic amino acid ligated to the polypeptide comprises lysine. 11. The peptide nucleic acid according to claim 9 , wherein at least two bases are 2-aminopyridine Bases. 12. The peptide nucleic acid according to claim 9 , wherein the polypeptide comprises at least six sequential base-ligated N-(2-aminoethyl)-glycines. 13. The peptide nucleic acid according to claim 9 , in combination with a double stranded RNA, wherein the peptide nucleic acid forms a base sequence-selective triple helix with the double stranded RNA. 14. A peptide nucleic acid (PNA), comprising a polypeptide comprising a series of N-(2-aminoethyl)-glycines, each N-(2-aminoethyl)-glycine being ligated to a respective base, wherein at least one respective base comprises 2-aminopyridine, configured to form a triple helix in sequence-selective manner with a double stranded ribonucleic acid which is stable at 37° C. in a pH 7.4 aqueous buffer comprising 2 mM MgCl 2 , 90-mM KCl, 10 mM NaCl, and 50 mM potassium phosphate. 15. The peptide nucleic acid according to claim 14 , configured to form, in combination with a double stranded RNA, a base sequence selective triple helix with the double stranded RNA substantially without strand invasion. 16. The peptide nucleic acid according to claim 14 , wherein at least one N-(2-aminoethyl)-glycine ligated to the respective base comprises: 17. The peptide nucleic acid according to claim 14 , further comprising at least one amino acid ligated to the series of N-(2-aminoethyl)-glycines. 18. The peptide nucleic acid according to claim 17 , wherein the at least one amino acid comprises lysine. 19. The peptide nucleic acid according to claim 9 , wherein at least one N-(2-aminoethyl)-glycine ligated to the respective Base comprises:
Peptide-nucleic acids (PNAs) · CPC title
Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof · CPC title
Triple helix formation or other higher order conformations in hybridisation assays · CPC title
having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title
incorporating a peptide nucleic acid · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.